The more effective the vector, the less we need. By improving how efficiently a virus can deliver a payload, we can reduce the risk of toxicity and reduce the cost of gene therapies.
Our AI-first approach allows us to be ambitious in targeting tissues that are currently impossible or hard to reach. This can improve on existing targets and open up new treatment possibilities.
Pre-existing immunity to viral vectors excludes patients from accessing gene therapies. One of our core outputs is designing vectors to evade antibodies.
Making AAV,
better
Lir’s first mission is AAV, the most widely used viral vector in gene therapy. Our goal is to unlock AAV’s true potential by remapping the surface of the capsid. With our ground up AI approach and high-throughput dataset generation pipeline, we're designing viruses never seen before.
Lir is decoding viral vectors. nAAVigator® is a holistic viral design engine trained on our unique datasets. It's been engineered to model viral vectors at all levels.
The result: engineering for safety and efficacy simultaneously.
Lir operates an integrated lab-in-the-loop between our AI development and laboratory. High-throughput assays generate completely unique datasets which drive our AI models. We design precise experiments to go beyond what’s possible for viral vector design.
We're actively speaking with potential collaborators. If you're interested in how our precision viral engineering can help you please get in touch!
Contact us ↗
© 2025 Copyright: Lir Therapeutics